First pediatric LEMS option approved, disrupting market

7 May 2019
rare_diseases_credit_depositphotos

The US regulator has granted privately-held Jacobus Pharmaceutical approval for its rare disease therapy Ruzurgi (amifampridine), to treat children with Lambert-Eaton myasthenic syndrome (LEMS).

The decision marks the first US Food and Drug Administration approval of a treatment specifically for children with LEMS, a rare autoimmune disorder that affects the connection between nerves and muscles, causing weakness and other symptoms.

The approval caused shares in Catalyst Pharmaceuticals (Nasdaq: CPRX) to crater in morning trading, down almost 40%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical